抗EGFR再挑战在转移性结直肠癌三线治疗中的应用研究进展

Research Progress on Anti-EGFR Rechallenge for the Third-Line Therapy of Metastatic Colorectal Cancer

表皮生长因子受体(epidermal growth factor receptor,EGFR)单克隆抗体是治疗转移性结直肠癌患者的有效一线药物。然而,抗EGFR治疗后获得性耐药的出现限制了EGFR抑制剂在转移性结直肠癌持续治疗中的应用。基于分子生物学的研究,抗EGFR再挑战策略在RAS/BRAF野生型转移性结直肠癌患者二线治疗后的临床管理中具有潜在活性。全文综述了抗EGFR再挑战策略在转移性结直肠癌三线治疗中的疗效及其相关毒性,并探讨了疗效预测因素的研究进展,为临床实践和科学研究提供新的视角。

The epidermal growth factor receptor(EGFR) monoclonal antibody is an effective firstline drug for metastatic colorectal cancer patients. However, the emergence of acquired resistance after anti-EGFR therapy limits the use of EGFR inhibitors in the sustained treatment of metastatic colorectal cancer. Based on molecular biology research, the anti-EGFR rechallenge strategy has potential activity in clinical management of RAS/BRAF wild-type metastatic colorectal cancer patients after second-line treatment. This paper reviews the efficacy and related toxicity of the antiEGFR rechallenge strategy in the third-line treatment of metastatic colorectal cancer, as well as the prediction factors for efficay, to provid a new perspective for clinical practice and scientific research.